Correlation
The correlation between HIMS and HALO is 0.42, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
HIMS vs. HALO
Compare and contrast key facts about Hims & Hers Health, Inc. (HIMS) and Halozyme Therapeutics, Inc. (HALO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HIMS or HALO.
Performance
HIMS vs. HALO - Performance Comparison
Loading data...
Key characteristics
HIMS:
1.67
HALO:
0.58
HIMS:
2.39
HALO:
1.07
HIMS:
1.31
HALO:
1.19
HIMS:
3.11
HALO:
0.89
HIMS:
6.53
HALO:
2.15
HIMS:
30.02%
HALO:
14.00%
HIMS:
107.53%
HALO:
51.35%
HIMS:
-87.29%
HALO:
-74.26%
HIMS:
-17.72%
HALO:
-20.06%
Fundamentals
HIMS:
$11.73B
HALO:
$6.74B
HIMS:
$0.68
HALO:
$3.78
HIMS:
77.06
HALO:
14.48
HIMS:
4.87
HALO:
-2.50
HIMS:
6.57
HALO:
6.22
HIMS:
21.35
HALO:
13.91
HIMS:
$1.78B
HALO:
$1.08B
HIMS:
$1.33B
HALO:
$887.05M
HIMS:
$123.98M
HALO:
$699.60M
Returns By Period
In the year-to-date period, HIMS achieves a 133.91% return, which is significantly higher than HALO's 17.28% return.
HIMS
133.91%
70.88%
75.54%
177.66%
141.01%
41.61%
N/A
HALO
17.28%
-8.71%
16.33%
29.34%
6.84%
18.23%
12.04%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
HIMS vs. HALO — Risk-Adjusted Performance Rank
HIMS
HALO
HIMS vs. HALO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Hims & Hers Health, Inc. (HIMS) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
HIMS vs. HALO - Dividend Comparison
Neither HIMS nor HALO has paid dividends to shareholders.
Drawdowns
HIMS vs. HALO - Drawdown Comparison
The maximum HIMS drawdown since its inception was -87.29%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for HIMS and HALO.
Loading data...
Volatility
HIMS vs. HALO - Volatility Comparison
The current volatility for Hims & Hers Health, Inc. (HIMS) is 32.17%, while Halozyme Therapeutics, Inc. (HALO) has a volatility of 35.23%. This indicates that HIMS experiences smaller price fluctuations and is considered to be less risky than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
HIMS vs. HALO - Financials Comparison
This section allows you to compare key financial metrics between Hims & Hers Health, Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HIMS vs. HALO - Profitability Comparison
HIMS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Hims & Hers Health, Inc. reported a gross profit of 430.69M and revenue of 586.01M. Therefore, the gross margin over that period was 73.5%.
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported a gross profit of 216.46M and revenue of 264.86M. Therefore, the gross margin over that period was 81.7%.
HIMS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Hims & Hers Health, Inc. reported an operating income of 57.90M and revenue of 586.01M, resulting in an operating margin of 9.9%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported an operating income of 141.54M and revenue of 264.86M, resulting in an operating margin of 53.4%.
HIMS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Hims & Hers Health, Inc. reported a net income of 49.49M and revenue of 586.01M, resulting in a net margin of 8.4%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported a net income of 118.10M and revenue of 264.86M, resulting in a net margin of 44.6%.